Phase I Study of Bortezomib With or Without Total Marrow Irradiation (TMI) Using Intensity Modulated Radiation Therapy (IMRT) in Combination With Fludarabine (FLU) and Melphalan (MEL) as a Preparative Regimen for Allogeneic Hematopoietic Stem Cell (HSC) Transplantation in Patients With High Risk Multiple Myeloma.

Trial Profile

Phase I Study of Bortezomib With or Without Total Marrow Irradiation (TMI) Using Intensity Modulated Radiation Therapy (IMRT) in Combination With Fludarabine (FLU) and Melphalan (MEL) as a Preparative Regimen for Allogeneic Hematopoietic Stem Cell (HSC) Transplantation in Patients With High Risk Multiple Myeloma.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs Bortezomib (Primary) ; Fludarabine; Melphalan; Sirolimus; Tacrolimus
  • Indications Graft-versus-host disease; Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 19 Jul 2017 Planned End Date changed from 1 Sep 2017 to 1 Sep 2018.
    • 19 Jul 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
    • 19 Jul 2017 Status changed from active, no longer recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top